Empagliflozin as a novel therapy for cirrhotic refractory ascites: a randomized controlled study

Empagliflozin as a novel therapy for cirrhotic refractory ascites: a randomized controlled study

Abstract Background Cirrhotic refractory ascites (RA) patients have few alternatives for treatment. Empagliflozin is now known to have natriuretic and neurohormonal modulatory effects. This research investigated the safety and efficacy of empagliflozin in the management of RA when added to the stand...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed Fathy Bakosh, Ramy Mohamed Ghazy, Walid Ismail Ellakany, Ahmed Kamal
Format: Article
Language:English
Published: SpringerOpen 2024-10-01
Series:Egyptian Liver Journal
Subjects:
Ascites
Sodium-glucose transporter 2 inhibitors
Empagliflozin
Diuretics
Natriuretic agents
Online Access:https://doi.org/10.1186/s43066-024-00383-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s43066-024-00383-y

Similar Items